122 related articles for article (PubMed ID: 38450658)
21. New chemical tools for investigating human mitotic kinesin Eg5.
Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
[TBL] [Abstract][Full Text] [Related]
22. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
23. A structural model for monastrol inhibition of dimeric kinesin Eg5.
Krzysiak TC; Wendt T; Sproul LR; Tittmann P; Gross H; Gilbert SP; Hoenger A
EMBO J; 2006 May; 25(10):2263-73. PubMed ID: 16642039
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
25. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
26. Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5.
Alrazi IMD; Ogunwa TH; Kolawole AO; Elekofehinti OO; Omotuyi OI; Miyanishi T; Maruta S
J Biochem; 2021 Dec; 170(5):611-622. PubMed ID: 34264310
[TBL] [Abstract][Full Text] [Related]
27. Identifying and characterising promising small molecule inhibitors of kinesin spindle protein using ligand-based virtual screening, molecular docking, molecular dynamics and MM‑GBSA calculations.
Elseginy SA
J Comput Aided Mol Des; 2024 Apr; 38(1):16. PubMed ID: 38556596
[TBL] [Abstract][Full Text] [Related]
28. Circular RNA‑MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis.
Liu Y; Dong Y; Zhao L; Su L; Luo J
Int J Oncol; 2018 Oct; 53(4):1752-1762. PubMed ID: 30015883
[TBL] [Abstract][Full Text] [Related]
29. Insights into modulating the monastrol scaffold: Development of new pyrimidinones as Eg5 inhibitors with anticancer activity.
Thabit MG; Mostafa AS; Selim KB; Elsayed MAA; Nasr MNA
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200029. PubMed ID: 35642307
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
[TBL] [Abstract][Full Text] [Related]
31. A pathway of structural changes produced by monastrol binding to Eg5.
Maliga Z; Xing J; Cheung H; Juszczak LJ; Friedman JM; Rosenfeld SS
J Biol Chem; 2006 Mar; 281(12):7977-82. PubMed ID: 16434397
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and Biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5.
Raghav D; Sebastian J; Rathinasamy K
Int J Biol Macromol; 2018 Apr; 109():1189-1208. PubMed ID: 29162464
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC.
Indorato RL; DeBonis S; Garcia-Saez I; Skoufias DA
Front Oncol; 2022; 12():965455. PubMed ID: 36313676
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and molecular docking study of new monastrol analogues as kinesin spindle protein inhibitors.
El-Hamamsy MH; Sharafeldin NA; El-Moselhy TF; Tawfik HO
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000060. PubMed ID: 32452567
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
36. Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines.
Gonçalves IL; Rockenbach L; das Neves GM; Göethel G; Nascimento F; Porto Kagami L; Figueiró F; Oliveira de Azambuja G; de Fraga Dias A; Amaro A; de Souza LM; da Rocha Pitta I; Avila DS; Kawano DF; Garcia SC; Battastini AMO; Eifler-Lima VL
Medchemcomm; 2018 Jun; 9(6):995-1010. PubMed ID: 30108989
[TBL] [Abstract][Full Text] [Related]
37. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
[TBL] [Abstract][Full Text] [Related]
38. Binding patterns of inhibitors to different pockets of kinesin Eg5.
Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
[TBL] [Abstract][Full Text] [Related]
39. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.
Skoufias DA; DeBonis S; Saoudi Y; Lebeau L; Crevel I; Cross R; Wade RH; Hackney D; Kozielski F
J Biol Chem; 2006 Jun; 281(26):17559-69. PubMed ID: 16507573
[TBL] [Abstract][Full Text] [Related]
40. Monastrol, a selective inhibitor of the mitotic kinesin Eg5, induces a distinctive growth profile of dendrites and axons in primary cortical neuron cultures.
Yoon SY; Choi JE; Huh JW; Hwang O; Lee HS; Hong HN; Kim D
Cell Motil Cytoskeleton; 2005 Apr; 60(4):181-90. PubMed ID: 15751098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
